Zhejiang Hisun Pharmaceutical Co., Ltd., founded in 1956, is a listed company, a large production base of antibiotics/antineoplastic drugs in China, and a leading API company
Zhejiang Hisun Pharmaceutical Co., Ltd., founded in 1956, is a state-controlled listed company, headquartered in Taizhou City, Zhejiang Province, with more than 9,000 employees, and was listed on the Shanghai Stock Exchange in July 2000 (stock code: 600267). Hisun has successively won the titles of "National High-tech Enterprise", "National Innovative Enterprise", "Technological Innovation Demonstration Enterprise", "National Intellectual Property Pilot Enterprise", "Pharmaceutical Export Demonstration Base", National May Day Labor Award, etc., and has also won the "Top 10 Export-oriented Enterprise Brands", "Top 10 Innovative Enterprise Brands" and "Top 500 National Manufacturing Enterprises" for many times. In 2014, it was listed on the Fortune China 500 list and was shortlisted as one of the first batch of "three" enterprises in Zhejiang Province. "Hisun" and "HISUN" have been recognized as well-known trademarks in China, and have successfully completed the national task of "production of epoxides, a key intermediate of anti-influenza A drug Tamiflu", and have been praised by the State Council and relevant ministries and commissions, and separately commended by the provincial government.
Haizheng has established integrated pharmaceutical bases in Taizhou, Hangzhou, Zhejiang and Rudong, Jiangsu Province, mainly engaged in the research, production and sales of APIs and preparations in the fields of anti-tumor, anti-infection, cardiovascular, endocrine, immunosuppression, anti-depression, orthopedics, etc., with business covering more than 70 countries and regions around the world. In 2014, Hisun Pharmaceutical's sales revenue exceeded 10 billion yuan.
Hisun has established a state-recognized enterprise technology center and a post-doctoral research station, and has established R&D institutions in Beijing, Shanghai and other places. The annual R&D investment accounts for more than 8% of the industrial sales revenue, and there are nearly 1,200 R&D personnel, including 8 people in the national "Thousand Talents Program" and 19 people in the provincial "Thousand Talents Program". At the same time, it has carried out the creation of new drugs of its own brand around the two major fields of "biological drugs and chemical drugs", combined with 30 domestic universities and research institutes to develop in alliances, and has formed characteristics and advantages in the industrialization of characteristic APIs and high-end preparations.
Hisun actively promotes the process of innovation and internationalization of national medicine, implements the "five transformations", continuously promotes the integration of raw materials, the branding of preparations and the industrialization of bio-products, and has developed from a simple product export and trading partner to a strategic alliance with large international companies, from a single API export to the synchronization of APIs and independent brand preparations, and from customized production for large foreign companies to joint innovation and research and development.
Adhering to the mission of "persisting in drug innovation and achieving the dream of health" and carrying the vision of "becoming a widely respected global professional pharmaceutical company", Hisun will continue to integrate drug R&D and production resources, provide better products and services to customers around the world, and strive to realize Hisun's global and sustainable pharmaceutical Chinese dream.
